Nippon India Nifty Pharma ETF
Nippon India Mutual Fund · Equity ETFs · Direct Growth · AMFI 149008 · ISIN INF204KC1089
NAV₹29.186320 Nov 2026
3Y return+22.02%a year
5Y return+16.60%a year
Expense ratio0.23%₹1,756 Cr
Growth Score—
Returns
| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 7Y | 10Y | Since launch |
| Fund | +10.82% | +7.43% | +14.54% | +25.40% | +25.57% | +22.02% | +16.60% | — | — | +14.02% |
| NIFTY Pharma TRI | +10.85% | +7.49% | +14.67% | +25.66% | +25.86% | +22.31% | +16.87% | — | — | — |
| Category middle | +9.21% | +2.42% | +8.27% | +2.25% | +1.02% | +14.23% | +11.71% | +14.45% | +13.56% | — |
Risk (36 months)
| Volatility | 14.96% |
| Sharpe | 1.04 |
| Sortino | 1.72 |
| Beta | 1.00 |
| Alpha | +0.00% |
| Deepest fall | -20.98% |
| 1-year periods with a loss | 26% |
| 5Y SIP XIRR | +20.60% |
Top holdings (31 Oct 2026)
| Sun Pharmaceutical Industries Limited | 18.61% |
| Divi's Laboratories Limited | 12.28% |
| Laurus Labs Limited | 9.26% |
| Dr. Reddy's Laboratories Limited | 8.15% |
| Cipla Limited | 7.67% |
| Torrent Pharmaceuticals Limited | 6.71% |
| Lupin Limited | 4.83% |
| Aurobindo Pharma Limited | 4.59% |
| Glenmark Pharmaceuticals Limited | 3.42% |
| Zydus Lifesciences Limited | 3.05% |
| Alkem Laboratories Limited | 3.05% |
| Mankind Pharma Limited | 2.79% |
Sectors
| Pharmaceuticals & Biotechnology | 100.0% |
Calculated by Growth Analyser from AMFI NAVs and the fund house's disclosed portfolio. Up to 1 year: total return; longer: CAGR. Research and education only; not investment advice. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance does not indicate future returns.